Financials Adocia

Equities

ADOC

FR0011184241

Biotechnology & Medical Research

Market Closed - Euronext Paris 11:35:06 2024-04-26 am EDT 5-day change 1st Jan Change
8.43 EUR +4.46% Intraday chart for Adocia -0.24% -26.95%

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 114 68.66 57.65 58.24 33.82 120.5 120.5 -
Enterprise Value (EV) 1 81.31 46.15 57.73 77.56 33.82 162.1 97.95 58.15
P/E ratio 16.5 x -3.67 x -2.52 x -2.53 x -4.41 x 4.11 x 2.27 x 1.51 x
Yield - - - - - - - -
Capitalization / Revenue 2.11 x 8.44 x 8.44 x 9.62 x 1.95 x 26.8 x 2.41 x 1.4 x
EV / Revenue 1.51 x 5.67 x 8.45 x 12.8 x 1.95 x 26.8 x 1.96 x 0.68 x
EV / EBITDA 7.56 x -2.21 x -2.88 x - - 12 x 3.75 x 1.32 x
EV / FCF 14.7 x -3.95 x -2.62 x -3.96 x - 14.1 x 3.63 x 1.41 x
FCF Yield 6.8% -25.3% -38.2% -25.3% - 7.11% 27.6% 70.7%
Price to Book 2.5 x 2.46 x 9.14 x - - 17.6 x 3.51 x 1.6 x
Nbr of stocks (in thousands) 6,895 6,935 6,946 7,190 8,519 14,289 14,289 -
Reference price 2 16.54 9.900 8.300 8.100 3.970 8.430 8.430 8.430
Announcement Date 3/12/19 3/12/20 3/18/21 4/19/22 3/15/23 4/24/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 53.93 8.134 6.833 6.055 17.36 6.048 50 86
EBITDA 1 10.75 -20.86 -20.02 - - 10.3 26.1 44
EBIT 1 9.707 -22.02 -21.15 -19.37 -12.9 -14.24 24.1 40.6
Operating Margin 18% -270.73% -309.5% -319.83% -74.28% -235.52% 48.2% 47.21%
Earnings before Tax (EBT) - - -23.3 -22.75 -6.425 - - -
Net income 1 7.615 -18.6 -23.32 -22.75 -6.901 -21.16 26.6 40.1
Net margin 14.12% -228.71% -341.34% -375.79% -39.75% -349.9% 53.2% 46.63%
EPS 2 1.000 -2.700 -3.300 -3.200 -0.9000 2.050 3.720 5.600
Free Cash Flow 1 5.529 -11.67 -22.06 -19.6 - 8.8 27 41.1
FCF margin 10.25% -143.52% -322.83% -323.62% - 47.06% 54% 47.79%
FCF Conversion (EBITDA) 51.43% - - - - 85.44% 103.45% 93.41%
FCF Conversion (Net income) 72.61% - - - - 60.27% 101.5% 102.49%
Dividend per Share - - - - - - - -
Announcement Date 3/12/19 3/12/20 3/18/21 4/19/22 3/15/23 4/24/24 - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S1 2020 S2 2021 Q1 2021 Q2 2021 S1 2021 Q3 2021 Q4 2022 S1 2022 S2
Net sales 1.71 3.261 0.115 0.287 0.402 1.76 - 7.349 10.01
EBITDA - - - - - - - - -
EBIT 1 - - - -4.82 - -4.86 -4.86 - -
Operating Margin - - - -1,679.44% - -276.14% - - -
Earnings before Tax (EBT) 1 - - - -5.3 - -6.08 -6.08 - -
Net income 1 -12.99 - - -5.3 - -6.08 -6.08 4.252 -
Net margin -759.88% - - -1,846.69% - -345.45% - 57.86% -
EPS - - - - - -0.8600 - - -1.400
Dividend per Share - - - - - - - - -
Announcement Date 7/17/19 3/18/21 4/22/21 7/22/21 7/22/21 4/27/22 4/19/22 9/19/22 3/15/23
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - 0.08 19.3 - 3.3 - -
Net Cash position 1 32.7 22.5 - - - - 22.5 62.3
Leverage (Debt/EBITDA) - - -0.003997 x - - 0.3204 x - -
Free Cash Flow 1 5.53 -11.7 -22.1 -19.6 - 8.8 27 41.1
ROE (net income / shareholders' equity) 18.4% -50.4% -136% - - - - 75.1%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 6.610 4.030 0.9100 - - 0.4800 2.400 5.280
Cash Flow per Share 1.070 - - - - - - -
Capex 1 0.78 2.02 0.21 0.36 - 0.4 1 1.7
Capex / Sales 1.45% 24.82% 3% 5.96% - 2.14% 2% 1.98%
Announcement Date 3/12/19 3/12/20 3/18/21 4/19/22 3/15/23 4/24/24 - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
8.43 EUR
Average target price
9.7 EUR
Spread / Average Target
+15.07%
Consensus